By Jan HENNOP/AFP – Malaysia’s verdant, river-crossed state of Sarawak is charging ahead with plans to become a regional “green battery,” but its renewable energy dreams could come at serious environmental cost, experts warn.
Malaysia’s Largest Island State Aims to Be Region’s ‘Green Battery’

Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Sept. 15, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab.
COMPASSION-36 is the first global registrational Phase III trial of cadonilimab, currently ongoing in China, the U.S. and Europe. Its advancement represents a significant milestone in the global development and registration of cadonilimab, reflecting Akeso’s commitment to advancing cancer immunotherapy and addressing the limited survival benefits associated with single-target therapies.
Additional global multicenter registrational/Phase III clinical trials for cadonilimab are currently being prepared. Going forward, Akeso will continue to pursue a dual strategy of in-house development and open collaboration, leveraging high-quality global resources to accelerate the internationalization of cadonilimab and offer patients worldwide improved and more accessible treatment options.
Currently, immune checkpoint inhibitor (IO) combination therapies have become the standard first-line treatment for various advanced malignancies. However, for patients worldwide whose disease progresses after IO combination therapy, there is a lack of effective second-line treatment options. The very limited second-line treatment options for advanced malignancies drive the critical need to explore new therapeutic strategies. Cadonilimab-based combination therapies have shown substantial potential in overcoming IO resistance across multiple tumor types.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with approximately 865,000 new cases of liver cancer reported globally in 2022. The combination of atezolizumab and bevacizumab (A+T regimen) is the standard first-line therapy for advanced HCC, as recommended by the NCCN guidelines. However, for patients whose disease progresses after first-line A+T treatment, there is currently no FDA-approved second-line therapy available in the U.S., and also no approved treatment options from the NMPA in China. This creates a significant unmet need in the clinical management of these patients.
The potential of cadonilimab for the treatment of HCC has been validated in multiple studies. The promising data from the combination of cadonilimab and pulocimab (anti-VEGFR-2) in treating IO-resistant lung cancer was recently presented as an oral presentation at WCLC 2025, generating widespread attention within the industry. At the 2023 ESMO Asia Congress, a study was presented demonstrating that cadonilimab, combined with FOLFOX-HAIC as neoadjuvant therapy, achieved a 100% disease control rate (DCR) in patients with resectable multinodular HCC. Data presented at the 2023 ESMO Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC shows superior antitumor activity.
Akeso’s exploration of combination therapies with cadonilimab in the treatment of HCC offers a broad and effective approach to disease management. These combinations address both early and advanced stages of HCC and provide promising therapeutic options for a wide range of patients.
In addition to the international multicenter Phase II registrational study COMPASSION-36, patient enrollment for the Phase III clinical trial of cadonilimab as adjuvant therapy for high-risk recurrence following curative surgery for HCC has been completed. Furthermore, a Phase III registrational study of cadonilimab combined with lenvatinib and transarterial chemoembolization (TACE) for the treatment of intermediate to advanced unresectable HCC is currently ongoing.
Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc
Australian scientists who discovered how to “turn off” genes that make cancer cells grow are celebrating the next phase of development – with Pfizer’s first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation.
MELBOURNE, Australia, Sept. 15, 2025 /PRNewswire/ — Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc’s clinical drug candidate discovered from Oncology One’s out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical trial, a key milestone.
Quick facts: PF-07248144 is a selective catalytic inhibitor of KAT6 (KAT6A/B), members of the histone lysine acetyltransferase family of enzymes that are involved in regulating gene expression. In certain cancers, KAT6A/B gene activity is dysregulated promoting cancer cell growth. PF-07248144 suppresses this abnormal gene activity and thereby supresses cancer growth. Previous clinical trials have shown promise for treating advanced or metastatic hormone receptor positive, HER2-negative breast cancer.
Pfizer’s KATSIS-1 trial, a Phase 3 clinical trial of PF-07248144 combined with fulvestrant, is now published on clinicaltrials.gov. Reference ID NCT 07062965, “A study to Learn About the Study Medicine called PF-07248144 in Combination with Fulvestrant in People with HR-Positive, HER2 Negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment”. The KATSIS-1 trial will have a broad international footprint, seeking to enrol up to 400 subjects across many trial sites including Australian hospitals and specialty breast cancer units.
Although early detection has dramatically improved the overall survival rate of breast cancer, it is estimated that 10,000 – 12,000 Australians are currently living with metastatic disease. The most common cancer type, HR+ HER2- metastatic breast cancer, is responsible for approximately 2, 500 deaths each year, or six Australians per day, indicting a clear need for better treatment of this disease. This investigational drug provides new hope for people whose cancer has failed to respond to all previous lines of treatment.
The progress of PF-07248144 represents a major win for Oncology One and validation for the multiple research institutes, biotechnology companies and researchers who participated in the Cancer Therapeutics CRC (now Canthera Discovery) to translate this original Australian research into a promising investigational drug.
In 2009, the KAT6 project was licensed into the Cancer Therapeutics Cooperative Research Centre (CTx), Australia’s first cooperative drug discovery network funded by the Australian Federal Government and participating organisations. It was further developed by CTx and later licensed to Pfizer in 2018 by Oncology One (formerly CTxONE).
Oncology One Chair of Scientific Advisory Board, Professor Ian Street, said: “In the early 2000s at Walter and Eliza Hall Institute (WEHI), Anne Voss and Tim Thomas made foundational discoveries about KAT6A, a protein that is important for controlling gene expression during development and growth of some blood cancers. Many CTx research and industry partners – Monash Institute of Pharmaceutical Sciences, SYNthesis Med Chem, Peter MacCallum Cancer Centre, WEHI, CSIRO, Griffith University, St Vincent’s Institute of Medical Research, and the Children’s Cancer Institute, along with Pfizer, have worked together to develop a new drug that targets KAT6. This is a deeply inspiring story of collaboration in Australia’s medical research sector.”
If successful, PF-07248144 is on track to become a therapeutic in a completely new class of drugs, which essentially turns off cancer cells and stops them from multiplying.
Professor Ian Street, said: “I would like to congratulate the visionary and talented Australian scientists and clinicians who contributed to the discovery and development of PF-07248144 – and of course, share our sincere gratitude to Pfizer for backing this potential cancer therapeutic so quickly into a Phase 3 Clinical Trial.”
To learn more about investment or partnership opportunities with Oncology One, visit oncologyone.com.au.
About Oncology One
Oncology One Pty Ltd is a cancer research and drug development company. We work with partners to identify suitable programs and build value in high potential drug discovery projects. Oncology One has one out-licensed program and is a private company headquartered in Melbourne, Australia. For more information visit oncologyone.com.au.
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
Highlights:
- Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients.
- >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations.
- Sustained engagement of 12+ months with 54% persistence even in high-risk, elderly patients, far above typical digital health benchmarks (30–45%).
- Clinically meaningful reductions in admissions, readmissions, and overall care costs, directly aligned with payer and health system value-based care priorities.
- Clear multi-billion-dollar commercial opportunity, positioning Adherium’s Hailie® Smartinhaler® as a scalable, defensible platform for U.S. and global expansion.
MELBOURNE, Australia, Sept. 15, 2025 /PRNewswire/ — Adherium Limited (ASX: ADR), a global leader in connected respiratory health solutions, has today announced preliminary results from the groundbreaking iCARE study, a real-world study conducted in partnership Intermountain Health, a leading nonprofit US health provider, and CareCentra, an AI-driven prevention-as-a-service remote monitoring platform.
The iCARE study (‘the Study’) has resulted in significant positive clinical outcomes, including record adherence rates and consistent patient engagement for patients with COPD and asthma. The Study included the supply of 4,000 Halie® Smartinhalers®, supporting up to 2,500 COPD and asthma patients across five Intermountain Health facilities over two years.
Adherium Chief Executive Officer, Dawn Bitz, said: “By generating actionable patient data, including biometrics from Adherium’s Smartinhaler technology, the iCARE study demonstrates breakthrough adherence, unprecedented patient persistence, reduced hospitalisations, and significant potential cost savings. This data lays strong foundations for a scalable, value-based care model with global commercial relevance. We are now on track to close one of the largest historical gaps in respiratory management, unlocking value for patients, providers, payers, and investors alike.”
Analysis of the ~850 Intermountain Health patients enrolled in the Study revealed compelling clinical results. Adherence was evaluated in a subset of patients with connected controller inhalers and at least 30 days of inhalation data. Across this group, patients used their inhalers on average nearly two-thirds of the time, far higher than the roughly one-in-five times typically reported in these populations, marking one of the strongest independent, real-world adherence outcomes recorded in chronic respiratory care. Average two-week baseline adherence was 62%, with ~4 in 10 patients reaching the critical threshold of greater than 80% adherence, a level long associated with nearly 50% fewer respiratory attacks.
Separately, analysis of nearly 700 patients demonstrated clinically meaningful improvements across multiple dimensions of respiratory care including reductions in inpatient admissions, 30-day readmissions, average length of stay and lower reliance on rescue medications; resulting in decreases in overall cost of care.
The iCARE study also demonstrated strong persistence (“stickiness”) of the CareCentra remote monitoring platform, with more than half active users staying engaged for over a year, far outpacing expectations typically reported in behaviour -change program. Engagement was the highest in elderly, high-risk patients, including those with depression, proving that technology-enabled support can make a lasting difference even for the hardest to reach patients, and those least likely to adopt or sustain digital health interventions. These patients also represent the highest-cost segment of the healthcare system, requiring the most hospitalisations and readmissions.
Adherium Chief Executive Officer, Dawn Bitz, said: “These interim results prove that digital health can deliver both measurable patient impact and health system value at scale. By combining innovative connected inhaler technology with CareCentra’s AI-driven behavioural engagement, we are not only improving adherence but also validating a sustainable, value-based care model.
“At the same time, outpatient encounters are increasing, reflecting earlier, proactive interventions that prevent costly crisis-level exacerbations. Together, these shifts demonstrate iCARE’s potential to fundamentally bend the cost curve in respiratory disease management—an outcome highly aligned with payer priorities in both U.S. and Australian markets.”
Intermountain Health Research Director for Respiratory Care Clinical Services, Kim Bennion, said: “For patients living with chronic respiratory disease, what happens between clinic visits often determines whether their condition stabilises or escalates. Through the iCARE program with continuous respiratory monitoring and nudging technology, we are giving our patients the tools and support to stay on therapy, avoid hospitalisations, and maintain a higher quality of life. These early results affirm the power of technology-enabled care to extend our reach beyond the hospital and clinic walls.”
The Study also presents opportunities for deeper analysis by condition type (COPD vs. asthma), patient severity (e.g., prior hospitalisations, GINA or GOLD classifications), environmental and weather-related factors, and socioeconomic influences on participation and outcomes, said Bennion.
A statistically more comprehensive dataset with detailed breakdowns will be released later but these results already serve as a leading indicator of iCARE’s ability to sustain engagement over time, and to deliver enduring value for patients, payers, and health systems.
Commerical Significance
- Adherium considers these preliminary results to be material under Listing Rule 3.1 because they demonstrate the scalability of the Hailie® platform in a leading U.S. health system, providing clinical validation that supports commercial expansion opportunities and payer engagement.
- These results are preliminary in nature and further data and analysis will be required before final conclusions can be drawn. Accordingly, while the findings are encouraging, they should not be taken as guarantees of future outcomes.
- Whilst the Study is currently being delivered in a research framework, these positive results position Adherium for new contracts, expanded sales and reimbursement.
- The iCARE study is the largest real-world respiratory monitoring care program for chronic obstructive pulmonary disease (COPD) and asthma patients. The Study included the supply of 4,000 Hailie® sensors, supporting up to 2,500 chronic obstructive pulmonary disease (COPD) and asthma patients, across five Intermountain facilities over a two-year period, underscoring both the scale of the program and the commercial adoption of Adherium’s technology.
Background
- Pressing global challenge: Asthma and COPD affect 40M in the U.S. and over 700M worldwide, with poor adherence the biggest barrier to better outcomes.
- Closing the adherence gap: Real-world adherence is often just 20–40%. In iCARE, adherence improved by up to 235%.
- Gold standard achieved: One third of patients-maintained adherence levels of > 80% during the entirety of the study, compared to single-digit rates in earlier studies.
- Scale and persistence: Nearly 1,000 patients, with two-thirds of doses taken as prescribed and more than 9 in 10 remain active after a year. Results unmatched by other digital health programs.
- Engaging the hardest to reach: Over half of patients remained engaged for a year, with the strongest persistence among elderly, high-risk patients including those aged 70 to 80.
- Engine of iCARE: Powered by Adherium’s Hailie® Smartinhaler® technology, which captures use, identifies technique errors, and enables real-time intervention, turning data into action for patients and providers.
- System-level impact: Early results show fewer hospital admissions, fewer readmissions, shorter stays, and less reliance on rescue medications, translating to better patient lives and lower system costs.
- Economic relevance: COPD drives over $31B in U.S. healthcare costs annually. Adherium’s technology directly addresses payer and provider priorities in value-based care.
- Investor significance: Adherium is the data engine behind iCARE and owns the insight pipeline, positioning the company for a multi-billion-dollar global opportunity.
Forward-Looking Statements: This announcement may contain forward-looking statements. These statements are based on current expectations, assumptions and uncertainties, and actual results may differ materially from those expressed or implied. Adherium undertakes no obligation to update or revise forward-looking statements except as required by law.
Learn more at adherium.com
This ASX announcement was approved and authorised for release by the Board of Adherium.
Investor Enquiries
Adherium Limited
investors@adherium.com
About Adherium (ASX:ADR)
Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com
About CareCentra, Inc
CareCentra, Inc. is a patient behavior-shaping company based in the U.S. that enables value-based care through an AI-driven, prevention-as-a-service remote monitoring platform. The CareCentra platform for continuous connected care
leverages advanced decision science, nudge theory, behavior science and personal technologies to enable remote monitoring and coordinate care for patients across the entire spectrum of chronic and acute conditions. CareCentra’s AI-driven platform was proven to better patient outcomes and lower healthcare costs in
Randomized Clinical Trials and is now used at several U.S. health systems to reduce admission/readmission while increasing patient engagement and improving care plan adherence.
About Intermountain Health
Headquartered in Utah with locations in six Western states, Intermountain Health is a nonprofit health system comprising 34 hospitals, approximately 385 clinics, and medical groups with some 3,900 employed physicians and advanced care providers, as well as a health plan division called SelectHealth—serving more than one million members. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized for transforming healthcare by using evidence-based best practices to deliver high-quality outcomes at sustainable costs.
WePlay Teams Up with CHIBI MARUKO-CHAN to Celebrate Its Fourth Anniversary!
TOKYO, Sept. 15, 2025 /PRNewswire/ — The highly popular social entertainment app WePlay announced today that, to express gratitude for users’ longstanding support, it has invited the iconic Japanese anime IP “CHIBI MARUKO-CHAN” to join its anniversary celebration lineup.
Maruko Joins WePlay for a Surprise Party
From 12:00 PM on September 16 to 12:00 AM on September 26, Maruko will appear as a virtual guest for the very first time on WePlay’s voice rooms. She will interact closely with players, sharing cheerful greetings and delightful surprises. Maruko’s signature smile and everyday stories will bring a warm, healing vibe to the WePlay community.
Exclusive Fourth Anniversary Rewards
- Exclusive Maruko Virtual Gifts: Specially designed collectible items to make your interactions even more meaningful.
- Exclusive CHIBI MARUKO-CHAN avatar: Use the exclusive avatar to transform into Maruko and join the anniversary celebration;
- Will’s Birthday Surprise Party: Spend a heartwarming online celebration with Will and CHIBI MARUKO-CHAN.
CHIBI MARUKO-CHAN: A Beloved Cultural Icon
Originally created by Momoko Sakura, CHIBI MARUKO-CHAN is set in Shimizu City, Shizuoka Prefecture (now Shimizu Ward, Shizuoka City), and warmly depicts the everyday life of the Sakura family—especially Maruko, the second daughter and a third-grade elementary school student—as well as her family and friends. The series began serialization in Ribon (SHUEISHA) in 1986 and celebrated its 35th anniversary in 2021.
The television anime adaptation began airing in 1990 and is still broadcast every Sunday at 6 p.m. on the Fuji TV network. The show has also been broadcast in Greater China and many other regions, captivating audiences of all ages around the world and continuing to be beloved for generations.
Four Years of Connection, Same Original Mission
Since launching in Japan four years ago, WePlay has remained committed to creating fun, heartwarming, and diverse social experiences. Through this anniversary celebration, WePlay aims to deliver more surprises and lasting memories while embarking on the next exciting chapter together with its community.
About WePlay
WePlay, a global social entertainment platform under Singapore-based Wejoy, integrates games, entertainment, and social features. With a mission to “Bring joy and friends to young people around the world,” WePlay is committed to co-create an innovative era of gaming and social experiences.
Contact:qipeinan@wejoysg.com
Website:https://weplayapp.com/
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation ‘Data Mining Machine’ for Genomics
![]() |
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a “data mining machine,” the T7+ redefines high-throughput sequencing by combining daily output with ease of use and multi-omics versatility.
DNBSEQ-T7+
A New Era in High-Throughput Sequencing
The T7+ integrates MGI’s proprietary DNBSEQ™ technology with next-generation fluidics, optics, and bioinformatics, creating a platform that is faster, smarter, and more versatile than ever before. The compact system supports 1–4 flow cells per run, adapts to projects of any scale, and integrates every step—from DNB preparation to bioinformatics analysis—into a fully automated workflow.
Key technical highlights include:
- Throughput: More than 14 Tb/day (vs. 7 Tb/day on T7)
- Annual Capacity: Up to 35,000 whole-genome sequencing (WGS)
- Accuracy: >90% Q40 quality scores, validated in beta testing by leading labs
- Speed: PE150 reads in under 24 hours
- Flexibility: Configurable for mid- or large-scale studies
- Size Efficiency: 1 m²
- 7-in-1 Integration: Hardware + software architecture eliminates manual preparation steps
- Scanning Time: 50% reduced by the TDI(Time-Delay Integration) camera.
- One-Stop Workflow: Built-in automation from DNB preparation to bioinformatics
- Reduced energy consumption: Over 90% of transport links and certain reagents require no cold chain.
With these capabilities, the T7+ enables researchers to sequence 144 human genomes in a single day, accelerating breakthroughs in cancer genomics, rare disease research, and precision medicine.
From T7 to T7+: Continuing the T Series Legacy
The DNBSEQ-T7, launched in 2018, was a breakthrough in the T Series, setting a new benchmark for high-throughput sequencing by delivering up to 7 terabases (Tb) of data in 24 hours. With over 400 units installed at more than 200 leading institutions worldwide, such as national initiatives, including Thailand’s Genomics Thailand Initiative and Brazil’s largest genomic sequencing project. This milestone redefined sequencing speed and accessibility, cementing the T Series as a cornerstone of genomic innovation.
As sequencing becomes increasingly affordable, researchers are demanding instruments that deliver higher throughput, faster results, and uncompromising accuracy and quality. That’s why MGI developed the T7+, an advanced continuation of the T7 designed to deliver greater speed, scalability, high flexibility, and performance to meet the evolving demands of clinical research, population genomics, and large-scale sequencing projects.
T7 was a breakthrough in specs, while the T7+ breaks new ground in user experience.
Redefining High-Throughput Sequencing
T7+ solves the universal trade-offs researchers face—speed versus capacity, usability versus cost. By integrating 7-in-1 hardware, smartphone-like software, and modular-designed consumables, the T7+ makes sequencing as intuitive as using a smartphone. Its ability to support multi-omics applications—spatial omics, single-cell, proteomics, methylation—in one run enables concurrent data streams for large cohorts.
“The T7+ is more than just a sequencer—it is a bridge between scientific discovery and real-world health outcomes,” added Duncan Yu, President of MGI Tech. “With higher throughput, improved accuracy, and a smaller footprint, the T7+ empowers scientists to ask bigger questions and deliver insights faster. Every genome sequenced has the potential to accelerate rare disease diagnosis, guide precision oncology, and inform public health at scale.”
Early adopters of the T7+ are already deploying it in population-scale studies, where its short-read power, combined with cyclone long-read data, enhances structural variant detection and rare disease analysis. Others are pairing the T7+ with long-read platforms for single-cell studies, opening new opportunities in understanding genetic diversity and cellular complexity.
T7+ is now open to order. International shipments begin in late 2025.
OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine
Breakthrough Chewable Chlorogenic Acid Tablet Designed To Support Immunity, Cellular Vitality and Metabolism.
HONG KONG SAR – Media OutReach Newswire – 15 September 2025 – OROJIN™️, the breakthrough oral chewable tablet system was unveiled at BIOHK 2025, one of the world’s most influential biotechnology gatherings. Signalling the beginning of a new era in preventive medicine, OROJIN™️ was created to redefine the way people approach their health. More than a supplement, OROJIN™️ delivers a daily dose of chlorogenic acid, a powerful antioxidant that supports immunity, cellular vitality, and promotes metabolic harmony. A “Daily Act of Self-Respect”, OROJIN™️ empowers people everywhere to live stronger, healthier, and more fulfilled lives.

Science That Protects
Developed in collaboration with leading professors and medical pioneers from the Miskawaan Health Group (MHG) and Jiuzhang Biotech, OROJIN™️ is built on advanced research into chlorogenic acid, one of nature’s most potent antioxidant compounds. Extracted from Eucommia leaves using a comprehensive, proprietary system, its researched benefits include:
- Neutralizing free radicals that damage DNA and accelerate aging. 1
- Calming chronic inflammation, the root cause of many diseases.2
- Restoring healthy cell signalling and boosting natural energy transport in the body, leading to beneficial metabolic effects. 3
- Protecting vital organs, including the heart, liver, gut, and brain. 4
- Encouraging restful sleep, and supporting memory and focus. 5
A New Standard in Preventive Medicine
With OROJIN™️, science becomes simple, accessible, and actionable in everyday life. “OROJIN™️ is not just another product — it is the beginning of a movement,” said David Boehm, Chairman of OROJIN™️ and Miskawaan Health Group. “This launch represents a mindset shift, encouraging people to take a proactive interest and care in their own health and wellbeing journey. We are delighted to be part of a new and empowered approach to wellness that starts with daily proactive care,” he added.
Global Launch Celebration at BIOHK 2025
The launch celebrations were led by David Boehm, Chairman of OROJIN™️, and Miskawaan Health Group, and Zhang Jie, Founder and Chairman of Jiuzhang Biotech. They included a Ribbon Cutting Ceremony featuring the OROJIN PreventaPanda™️, a beloved symbol of proactive health.
References
- Ogawa H, et al. Chem Lett. 2023;52:524-527.
- Huang J, et al. Front Pharmacol. 2023 Sep 13:14:1218015.
- Meng S, et al. Evid Based Complement Alternat Med. 2013:2013:801457.
- Lu H, et al. Compr Rev Food Sci Food Saf. 2020;19:3130-3158.
- Saitou K, et al. Nutrients. 2018;10:1337.
Disclaimer: This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
Hashtag: #OROJIN
The issuer is solely responsible for the content of this announcement.
About OROJIN™️
OROJIN™️ is the world’s first complete preventive wellness system, built on decades of scientific research and inspired by the belief that prevention is the highest form of care. Designed for global impact, OROJIN™️ empowers individuals everywhere to live longer, stronger, and with self-respect.
About Miskawaan Health Group
Miskawaan Health Group (MHG) combines cutting-edge German medical diagnostics with the wisdom of traditional holistic healing practices. The mission: to integrate the latest advancements in medical science with natural therapies to deliver personalised, patient-centred care.
About Jiuzhang Biotech
Jiuzhang Biotech is a pioneer in botanical medicine and natural product research. With more than 80 patents in proprietary extraction technologies, the company integrates traditional Chinese medicine with modern biotechnology to deliver pharmaceutical-grade raw materials and science-backed wellness solutions.
OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine
Breakthrough Chewable Chlorogenic Acid Tablet Designed To Support Immunity, Cellular Vitality and Metabolism.
HONG KONG SAR – Media OutReach Newswire – 15 September 2025 – OROJIN™️, the breakthrough oral chewable tablet system was unveiled at BIOHK 2025, one of the world’s most influential biotechnology gatherings. Signalling the beginning of a new era in preventive medicine, OROJIN™️ was created to redefine the way people approach their health. More than a supplement, OROJIN™️ delivers a daily dose of chlorogenic acid, a powerful antioxidant that supports immunity, cellular vitality, and promotes metabolic harmony. A “Daily Act of Self-Respect”, OROJIN™️ empowers people everywhere to live stronger, healthier, and more fulfilled lives.

Science That Protects
Developed in collaboration with leading professors and medical pioneers from the Miskawaan Health Group (MHG) and Jiuzhang Biotech, OROJIN™️ is built on advanced research into chlorogenic acid, one of nature’s most potent antioxidant compounds. Extracted from Eucommia leaves using a comprehensive, proprietary system, its researched benefits include:
- Neutralizing free radicals that damage DNA and accelerate aging. 1
- Calming chronic inflammation, the root cause of many diseases.2
- Restoring healthy cell signalling and boosting natural energy transport in the body, leading to beneficial metabolic effects. 3
- Protecting vital organs, including the heart, liver, gut, and brain. 4
- Encouraging restful sleep, and supporting memory and focus. 5
A New Standard in Preventive Medicine
With OROJIN™️, science becomes simple, accessible, and actionable in everyday life. “OROJIN™️ is not just another product — it is the beginning of a movement,” said David Boehm, Chairman of OROJIN™️ and Miskawaan Health Group. “This launch represents a mindset shift, encouraging people to take a proactive interest and care in their own health and wellbeing journey. We are delighted to be part of a new and empowered approach to wellness that starts with daily proactive care,” he added.
Global Launch Celebration at BIOHK 2025
The launch celebrations were led by David Boehm, Chairman of OROJIN™️, and Miskawaan Health Group, and Zhang Jie, Founder and Chairman of Jiuzhang Biotech. They included a Ribbon Cutting Ceremony featuring the OROJIN PreventaPanda™️, a beloved symbol of proactive health.
References
- Ogawa H, et al. Chem Lett. 2023;52:524-527.
- Huang J, et al. Front Pharmacol. 2023 Sep 13:14:1218015.
- Meng S, et al. Evid Based Complement Alternat Med. 2013:2013:801457.
- Lu H, et al. Compr Rev Food Sci Food Saf. 2020;19:3130-3158.
- Saitou K, et al. Nutrients. 2018;10:1337.
Disclaimer: This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
Hashtag: #OROJIN
The issuer is solely responsible for the content of this announcement.
About OROJIN™️
OROJIN™️ is the world’s first complete preventive wellness system, built on decades of scientific research and inspired by the belief that prevention is the highest form of care. Designed for global impact, OROJIN™️ empowers individuals everywhere to live longer, stronger, and with self-respect.
About Miskawaan Health Group
Miskawaan Health Group (MHG) combines cutting-edge German medical diagnostics with the wisdom of traditional holistic healing practices. The mission: to integrate the latest advancements in medical science with natural therapies to deliver personalised, patient-centred care.
About Jiuzhang Biotech
Jiuzhang Biotech is a pioneer in botanical medicine and natural product research. With more than 80 patents in proprietary extraction technologies, the company integrates traditional Chinese medicine with modern biotechnology to deliver pharmaceutical-grade raw materials and science-backed wellness solutions.